Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phage Therapy (BX211) in Diabetic Foot Osteomyelitis
NCT05177107Phase 2Terminated
- Sponsor
- BiomX
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BX211 in diabetic foot osteomyelitis (DFO) (2 arms), sponsored by BiomX. Primary endpoint: Percent area reduction of study ulcer at Week 13. Started Nov 2021; status: terminated.
02
Drugs
BX211
03
Conditions
diabetic foot osteomyelitis (DFO)
Beyond the preview
Go deeper on NCT05177107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177107.